FGF10 and FGF21 as Regulators in Adipocyte Development and Metabolism

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 11, Iss. 4, 2011-12 ,pp. : 302-309

Bentham Science Publishers

Access to resources Recommend Favorite

The role of gp130/IL-6 cytokines in the development of pulmonary fibrosis: critical determinants of disease susceptibility and progression?

By Knight D.A.   Ernst M.   Anderson G.P.   Moodley Y.P.   Mutsaers S.E.  

Pharmacology and Therapeutics, Vol. 99, Iss. 3, 2003-09 ,pp. : 327-338

Elsevier

Access to resources Recommend Favorite

gp130-mediated signalling as a therapeutic target

By Ohtani T.   Ishihara K.   Atsumi T.   Yoshida Y.   Nishida K.   Narimatsu M.   Shirogane T.   Hibi M.   Hirano T.  

Expert Opinion on Therapeutic Targets, Vol. 4, Iss. 4, 2000-08 ,pp. : 459-479

Informa Healthcare

Access to resources Recommend Favorite

gp130: a promising drug target for cancer therapy

By Xu Shili   Neamati Nouri  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 11, 2013-11 ,pp. : 1303-1328

Informa Healthcare

Access to resources Recommend Favorite

The Development of Cytokine Receptor Antagonists as Potential Therapeutic Agents for the Myeloproliferative Disorders

By  

Current Pharmaceutical Design, Vol. 8, Iss. 5, 2002-03 ,pp. : 357-368

Bentham Science Publishers

Access to resources Recommend Favorite